MIST Stock Summary and Trading Ideas (Milestone Pharmaceuticals - Common Shares | NASDAQ:MIST)

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

Milestone Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol MIST.

As of April 21, 2026, MIST stock price declined to $1.92 with 1,729,685 million shares trading.

MIST has a beta of 3.42, meaning it tends to be more sensitive to market movements. MIST has a correlation of 0.26 to the broad based SPY ETF.

MIST has a market cap of $225.92 million. This is considered a Small Cap stock.

Last quarter Milestone Pharmaceuticals - Common Shares reported $2 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $346,000 and exceeded earnings estimates by $.02.

In the last 3 years, MIST traded as high as $4.49 and as low as $.63.

The top ETF exchange traded funds that MIST belongs to (by Net Assets): QQQS, GWX.

MIST has outperformed the market in the last year with a price return of +90.1% while the SPY ETF gained +38.4%. However, in the short term, MIST had mixed performance relative to the market. It has underperformed in the last 3 months, returning -4.5% vs +3.0% return in SPY. But in the last 2 weeks, MIST shares have fared better than the market returning +19.3% compared to SPY +6.8%.

MIST support price is $1.89 and resistance is $2.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIST shares will trade within this expected range on the day.